CIO at Guardant Health (NASDAQ: GH) sells 40K shares after option exercises

Rhea-AI Filing Summary

Guardant Health Chief Information Officer Kumud Kalia exercised stock options and sold shares on March 4, 2026. He exercised multiple stock option awards, converting them into common stock at exercise prices including $47.20, $74.00, $32.86, $28.37, and $28.61 per share.

On the same date, he sold a total of 40,000 shares of Guardant Health common stock in open-market transactions at weighted average prices of about $95.12 and $95.73 per share, across ranges disclosed in the footnotes. After these trades, he directly held 37,643 shares of common stock.

The option awards he exercised were originally granted between April 20, 2020 and November 8, 2024 and vest over three- or four-year schedules, with initial portions vesting on specified dates and remaining shares vesting in equal monthly installments thereafter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		2,119	A	$47.2	36,643	D
Common Stock	03/04/2026		M		15,000	A	$47.2	51,643	D
Common Stock	03/04/2026		M		1,000	A	$74	52,643	D
Common Stock	03/04/2026		M		5,000	A	$32.86	57,643	D
Common Stock	03/04/2026		M		10,000	A	$28.37	67,643	D
Common Stock	03/04/2026		M		10,000	A	$28.61	77,643	D
Common Stock	03/04/2026		S		26,980	D	$95.119(1)	50,663	D
Common Stock	03/04/2026		S		13,020	D	$95.7258(2)	37,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$47.2	03/04/2026		M			2,119	(3)	11/07/2032	Common Stock	2,119	$0	49,305	D
Stock Option (Right to Buy)	$47.2	03/04/2026		M			15,000	(3)	11/07/2032	Common Stock	15,000	$0	34,305	D
Stock Option (Right to Buy)	$74	03/04/2026		M			1,000	(4)	04/20/2030	Common Stock	1,000	$0	27,670	D
Stock Option (Right to Buy)	$32.86	03/04/2026		M			5,000	(5)	06/09/2033	Common Stock	5,000	$0	6,414	D
Stock Option (Right to Buy)	$28.37	03/04/2026		M			10,000	(6)	12/13/2033	Common Stock	10,000	$0	9,410	D
Stock Option (Right to Buy)	$28.61	03/04/2026		M			10,000	(7)	11/08/2034	Common Stock	10,000	$0	25,721	D

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.460 to $95.455. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $95.46 to $96.14. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. This represents a stock option award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on November 7, 2023 and the remaining 75% of the shares vests in equal monthly installments over the remaining three-year period thereafter.

4. This represents a stock option award granted on April 20, 2020 that vests over a four-year period. 25% of the shares subject to such award vested on January 7, 2021 and the remaining 75% of the shares vested in equal monthly installments over the three-year period thereafter.

5. This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.

6. This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.

7. This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Kumud Kalia	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health (GH) insider Kumud Kalia report in this Form 4?

Kumud Kalia reported exercising multiple stock options and selling common shares of Guardant Health on March 4, 2026. The filing details option exercises into common stock followed by open-market sales totaling 40,000 shares, with remaining direct ownership of 37,643 shares afterward.

How many Guardant Health (GH) shares did the CIO sell in this transaction?

The Chief Information Officer sold 40,000 shares of Guardant Health common stock on March 4, 2026. These were executed in two open-market sale transactions of 26,980 and 13,020 shares, at weighted average prices around $95.12 and $95.73 per share, respectively.

At what prices were the Guardant Health (GH) insider sales executed?

The reported sales used weighted average prices of about $95.1190 and $95.7258 per share. Footnotes state the 26,980-share block traded between $94.460–$95.455, and the 13,020-share block between $95.46–$96.14, with full breakdowns available on request.

What stock options did the Guardant Health (GH) CIO exercise?

He exercised several stock option awards granted on April 20, 2020, November 7, 2022, June 9, 2023, December 13, 2023, and November 8, 2024. These options vest over three or four years, with initial tranches vesting on specified dates and the rest monthly thereafter.

How many Guardant Health (GH) shares does the CIO own after these trades?

After completing the option exercises and share sales on March 4, 2026, Kumud Kalia directly owned 37,643 shares of Guardant Health common stock. This post-transaction holding figure is explicitly reported as the total shares following the final sale transaction in the filing.

Were the Guardant Health (GH) insider sales made in single or multiple trades?

The 40,000 Guardant Health shares were sold in multiple transactions within price ranges. One block traded between $94.460–$95.455 and the other between $95.46–$96.14. Weighted average prices are reported, with full per-trade details available upon request.